

ADHD Guideline Committee Meeting 12

Date and Time: Tuesday 23 May 2017, 10:00-17:00

Place: Boardroom, National Guideline Centre

Minutes: Confirmed

Present:

Gillian Baird (GB)	Professor of Paediatric Neurodisability and Consultant Developmental Paediatrician, Chair
Philip Asherson (PA)	Professor of Psychiatry and Honorary Consultant Psychiatrist
Polly Branney (PB)	General Practitioner
Poppy Ellis Logan (PEL)	Lay Member
Jean Fitzpatrick (JF)	Lay Member
Gisli Gudjonsson (GG)	Professor of Psychology
Chris Hollis (CH)	Professor of Child & Adolescent Psychiatry and Consultant in Developmental Neuropsychiatry
Nicole Horwitz (NH)	Consultant Community Paediatrician
Jen Lewis-Neill (JLN)	Clinical Lead/Independent Nurse Prescriber
Karen Pratt (KP)	Paediatric Nurse Specialist for Neurodisability
Kapil Sayal (KS)	Professor of Child & Adolescent Psychiatry and Honorary Consultant Psychiatrist
David Traxson (DT)	Educational Psychologist
Jody Warner-Rogers (JWR)	Consultant Clinical Psychologist and Paediatric Neuropsychologist

NICE team

Ben Doak (BD)	Guidelines Commissioning Manager
---------------	----------------------------------

NGC technical team

Rebecca Boffa (RB)	Research Fellow (items 1- 5)
Margaret Constanti (MC)	Senior Health Economist
James Gilbert (JG)	Senior Research Fellow
Samantha Jones (SJ)	Project Manager (notes)
Kate Kelley (KK)	Guideline Lead
Rafina Yarde (RY)	Research Fellow

Apologies

Marios Adamou (MA)	Consultant Psychiatrist (adults) and Visiting Professor
Katie Broomfield (KB)	Document Editor/Process Assistant, NGC
Jonathan Rackham (JR)	Lay Member
Emily Simonoff (ES)	Professor of Child & Adolescent Psychiatry, Clinical Specialist
Ian Wong (IW)	Professor of Pharmacy Practice and Medicine Evaluation

Notes

1. The Chair welcomed the group to the twelfth meeting of this GC. Apologies were received from MA, AA, KB, JR, ES and IW.
2. The Chair reviewed and requested updates to the declarations of interest register. The Chair declared that in relation to previous declarations recorded in the DOI register, for this meeting, the following actions should apply:
 - Philip Asherson should withdraw from discussions on the pharmacological efficacy review and recommendations.
 The following new declarations were received for this meeting:

GC Declarations of Interest			
N.B. The Chair and GC members were recruited to this guideline using NICE DOI policy published September 2014.			
Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chair's action
PA	<ol style="list-style-type: none"> 1. Attended advisory board meeting for the use of drugs in sports. Advice was given on the diagnostic process required to confirm the diagnosis of ADHD with sufficient certainty to allow for exemption of banned drugs during sporting events. A small fee plus travel costs were paid to King's College London. 2. Attended the world congress on ADHD on 18/19th April 2017. I gave a talk on what is lacking in the DSM-5 criteria for ADHD in adults. The congress organisers paid for my travel and 2 nights' accommodation during the conference. 3. Ran a workshop on the treatment of ADHD with comorbidity. The workshop was run at two events on 9th and 10th May in Newcastle and London respectively. The event was organised as a training day by Shire, and a speaker fee and travel costs were paid to King's College London. 	<ol style="list-style-type: none"> 1. Non-personal financial non-specific 2. Non-personal financial non-specific 3. Non-personal financial specific 	<ol style="list-style-type: none"> 1. Declare and participate 2. Declare and participate 3. Declare and participate
NICE DOI policy classifications are: <ul style="list-style-type: none"> • Personal financial specific • Personal financial non-specific • Personal non-financial specific • Personal non-financial non-specific • Non-personal financial specific • Non-personal financial non-specific 			

3. The meeting notes and NICE minutes of the last meeting were reviewed by the committee. No amendments were required. The notes and NICE minutes were then agreed as a true and accurate record of the meeting.

4. JG presented the new clinical evidence identified by rerun searches for the pharmacological efficacy and non-pharmacological efficacy reviews. MC presented the health economic evidence.
5. KK and RB presented the clinical evidence for the pharmacological safety review.
6. MC presented health economic modelling results.
7. The GC reviewed and amended the draft recommendations. PA left the room for discussions on the first-line pharmacological treatment recommendations.
8. AOB: Action points were assigned and next steps discussed.

Date, time and venue of the next meeting

Committee Meeting 12: Tuesday 04 July, 10:00-16:30, NGC Boardroom, 180 Great Portland Street, London W1W 5QZ